{"id":"W2892245423","doi":"10.1200/jco.2016.34.15_suppl.tps8574","title":"Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Nintedanib; Internal medicine; Clinical endpoint; Placebo; Docetaxel; Phases of clinical research; Oncology; Bevacizumab; Maintenance therapy; Pemetrexed; Progression-free survival; Gastroenterology; Chemotherapy; Surgery; Clinical trial; Cisplatin; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001853981,0.002170115,0.002693298,0.0006545949,0.0005635762,0.001117022,0.001326588,0.001646852,0.008844797],"category_scores_gemma":[0.001148206,0.001067051,0.001721702,0.0004141412,0.001448946,0.001252722,0.0005074075,0.003653679,0.001890368],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009134846,"about_ca_system_score_gemma":0.001837693,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001117757,"about_ca_topic_score_gemma":0.003074038,"domain_scores_codex":[0.999625,0.0001815257,0.00002050425,0.00007565104,0.00003000937,0.00006726632],"domain_scores_gemma":[0.9994124,0.0001102424,0.0001132898,0.00004582014,0.00003998261,0.000278178],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9586486,0.02272722,0.0003546717,0.0005995109,0.0005101538,0.00003015345,0.00004912925,0.0003403259,0.00507575,0.0001517966,0.00117674,0.01033598],"study_design_scores_gemma":[0.9298958,0.06822211,0.0005573752,0.00001581515,0.0001657299,0.00001631805,0.00001383783,0.0002709163,0.0002957649,0.00008449147,0.0004528175,0.000009131015],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9658062,0.004262579,0.001641718,0.001164541,0.001385726,0.01864504,0.002464204,0.000482911,0.004147123],"genre_scores_gemma":[0.957127,0.00352532,0.003799676,0.00209986,0.0005447699,0.02122132,0.002269179,0.00006766803,0.009345147],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008844797,"threshold_uncertainty_score":0.02958876,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05603232695569429,"score_gpt":0.400165441583721,"score_spread":0.3441331146280268,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}